AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$ANTX

Readnour Robin Shane sold $7K of ANTX (indirect holdings)

Readnour Robin Shane sold 1,108 indirectly-held shares of AN2 Therapeutics, Inc. (ANTX) at $6.02 across 2 trades on 2026-09-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Readnour Robin Shane
Published Sep 11, 2026, 11:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 11:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ANTX
Neutral
high confidence
Mentioned
$ANTX
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANTXNeutralLow
01

Why it matters

The disclosed sale is routine and low in monetary value, offering little actionable insight.

02

Market read

A minor insider sale with limited market impact.

03

What to watch

Potential upcoming clinical data could influence future insider activity.

Relevance 2/10Novelty 4/10Timing: filing posted on 2026-09-11

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$ANTXNeutralHigh confidence
Context

Director Readnour Robin Shane sold 1,108 shares for $6,674.93 via a 10b5-1 plan, reducing his holdings to 624,765 shares.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale amount is small relative to market cap and typical insider trading volumes.

Market effects

Sector

None; biotech sector unchanged.

Regional

No regional effect.

Global

Minimal.

Counterpoint

What could challenge this read

Even small insider sales can signal lack of confidence; monitor for further disposals.

Key entities

  • Individual
    Readnour Robin Shane

    Director of AN2 Therapeutics, Inc.

  • Company
    AN2 Therapeutics, Inc.

    Biopharmaceutical company developing therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ANTX insider trading history →

Related articles

AUG 11
$ANTXMed

AN2 Therapeutics, Inc. (ANTX): Results of Operations and Financial Condition

AN2 Therapeutics, Inc. (ANTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights Expanding Phase 2 study start-up activities to support global trial of oral epetraborole in polycythemia vera Enrollment ongoing in Phase 2 investigator-initi

SEC EDGAR 8-K6 min